-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Protagenic Therapeutics (OTCMKTS:PTIX) Share Price Passes Below 200-Day Moving Average of $0.76
Protagenic Therapeutics (OTCMKTS:PTIX) Share Price Passes Below 200-Day Moving Average of $0.76
Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.
Protagenic Therapeutics Price Performance
The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.
Get Protagenic Therapeutics alerts:Institutional Trading of Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.
Protagenic Therapeutics Company Profile
(Get Rating)Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.
在周二的交易中,Protag Treateutics,Inc.(OTCMKTS:PTIX-GET评级)的股价跌破了200日移动平均线。该股的200日移动均线为0.76美元,最低交易价格为0.67美元。Protag Treateutics的股票最后交易价格为0.68美元,成交量为18,049股。
Protagenic Therapeutics Price Performance
他汀类治疗药物的价格表现
The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.
该业务的50日移动均线价格为0.66美元,其200日移动均线价格为0.76美元。该公司的负债权益比率为0.04,速动比率为19.47,流动比率为19.47。
Institutional Trading of Protagenic Therapeutics
前列腺素治疗药物的制度性交易
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.
一家机构投资者最近提高了其在普罗吉治疗公司股票的头寸。根据复兴科技有限公司在最近向美国证券交易委员会(美国证券交易委员会)披露的信息,该公司在第一季度将其在普罗吉治疗公司(场外交易代码:PTIX-GET评级)的股份增加了69.2%。该基金在此期间额外购买了41,800股后,持有这家生物技术公司的102,200股股票。截至最近提交给美国证券交易委员会的文件,复兴技术公司拥有普罗吉治疗公司约0.59%的股份,价值83,000美元。该公司3.50%的股份目前由机构投资者持有。
Protagenic Therapeutics Company Profile
普罗他尼治疗公司简介
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
前列基因治疗公司是一家生物制药公司,致力于发现和开发治疗与压力相关的神经精神和情绪障碍的疗法。它的先导化合物是PT00114,这是Teneurin羧基末端相关肽的合成形式,Teneurin羧基末端相关肽是一种内源性大脑信号肽,可以抑制过度活跃的应激反应。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免费获取StockNews.com关于前列腺素治疗(PTIX)的研究报告
- 这三份报告将告诉我们许多关于当前经济的情况。
- 下面的五个是不是打得太高了?
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普罗汀治疗日报》的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯,收到对Protag Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧